Abeona Therapeutics Inc. (ABEO - Free Report) was a big mover last session, as its shares rose a little over 11% on the day. The move came on the back of Data Safety Monitoring Board’s approval of ABO-102 dose escalation for second cohort in Phase 1/2 clinical trial for Sanfilippo Syndrome Type A. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.69 to $6.57 in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days while the Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Abeona Therapeutics currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
A better-ranked stock in the med-biomed/gene space is Geron Corporation (GERN - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ABEO going up? Or down? Predict to see what others think: Up or Down
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>